The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and wnt inhibitors in young women with hypothalamic amenorrhea

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2252-E2258

  Foo, Joo Pin ^a   Polyzos, Stergios A ^a   Anastasilakis, Athanasios D ^b   Chou, Sharon ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b 424 General Army Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; CALCIUM; CREATININE; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; LEPTIN; METRELEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GENETIC MARKER; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG MECHANISM; EVENING DOSAGE; FEMALE; HUMAN; HYPOLEPTINEMIA; HYPOTHALAMIC AMENORRHEA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; ADOLESCENT; AMENORRHEA; ANALOGS AND DERIVATIVES; BLOOD; GENETIC MARKER; HORMONE SUBSTITUTION; HYPOTHALAMIC DISEASES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AMENORRHEA; BONE MORPHOGENETIC PROTEINS; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTORS; GENETIC MARKERS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHALAMIC DISEASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; RANK LIGAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84910018198     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2491     Document Type: Article

References (37)

1. Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med. 2010;363: 365-371.
2. Miller KK, Lawson EA, Mathur V, et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab. 2007;92: 1334-1339.
3. Colvard DS, Eriksen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA. 1989;86: 854-857.
4. Misra M, Klibanski A. Bone health in anorexia nervosa. Curr Opin Endocrinol Diabetes Obes. 2011;18: 376-382.
5. Swenne I, Stridsberg M. Bone metabolism markers in adolescent girls with eating disorders and weight loss: effects of growth, weight trend, developmental and menstrual status. Arch Osteoporos. 2012; 7: 125-133.
6. Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG. Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab. 2002;87: 3162-3168.
7. Foo JP, Hamnvik OP, Mantzoros CS. Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations. Metabolism. 2012;61: 899-905.
8. Miller KK, Parulekar MS, Schoenfeld E, et al. Decreased leptin levels in normal weightwomenwith hypothalamic amenorrhea: the effects of body composition and nutritional intake. J Clin Endocrinol Metab. 1998;83: 2309-2312.
9. Sienkiewicz E, Magkos F, Aronis KN, et al. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism. 2011;60: 1211-1221.
10. Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA. 2011; 108: 6585-6590.
11. Warren MP, Brooks-Gunn J, Hamilton LH, Warren LF, Hamilton WG. Scoliosis and fractures in young ballet dancers. Relation to delayed menarche and secondary amenorrhea.NEngl J Med. 1986; 314: 1348-1353.
12. Ruhl CE, Everhart JE. Relationship of serum leptin concentration with bone mineral density in the United States population. J Bone Miner Res. 2002;17: 1896-1903.
13. Filip R, Raszewski G. Bone mineral density and bone turnover in relation to serum leptin, α-ketoglutarate and sex steroids in overweight and obese postmenopausal women. Clin Endocrinol (Oxf). 2009;70: 214-220.
14. Zhong N, Wu XP, Xu ZR, et al. Relationship of serum leptin with age, body weight, body mass index, and bone mineral density in healthy mainland Chinese women. Clin Chim Acta. 2005;351: 161-168.
15. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111: 305-317.
16. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434: 514-520.
17. Chan JL, Mietus JE, Raciti PM, Goldberger AL, Mantzoros CS. Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clin Endocrinol (Oxf). 2007;66: 49-57.
18. Cifuentes M, Advis JP, Shapses SA. Estrogen prevents the reduction in fractional calcium absorption due to energy restriction in mature rats. J Nutr. 2004;134: 1929-1934.
19. Dick IM, Devine A, Beilby J, Prince RL. Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women. Am J Physiol Endocrinol Metab. 2005;288: E430-E435.
20. Coen G, Ballanti P, Fischer MS, et al. Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis. 2003;42: 1036-1042.
21. Ahmadi F, Salari S, Maziar S, Esfahanian F, Khazaeipour Z, Ranjbarnovin N. Relationship between serum leptin levels and bone mineral density and bone metabolic markers in patients on hemodialysis. Saudi J Kidney Dis Transpl. 2013;24: 41-47.
22. Grethen E, Hill KM, Jones R, et al. Serum leptin, parathyroid hormone, 1, 25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97: 1655-1662.
23. Kovesdy CP, Molnar MZ, Czira ME, et al. Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin J Am Soc Nephrol. 2010;5: 2297-2304.
24. Bhadada SK, Bhansali A, ShahVN, RaoDS. Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. Singapore Med J. 2011;52: 890-893.
25. Hoang D, Broer N, Roman SA, et al. Leptin signaling and hyperparathyroidism: clinical and genetic associations. J Am Coll Surg. 2014;218: 1239-1250.
26. Haden ST, Brown EM, Hurwitz S, Scott J, El-Hajj Fuleihan G. The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol (Oxf). 2000;52: 329-338.
27. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423: 337-342.
28. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000; 15: 2-12.
29. MaYL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142: 4047-4054.
30. Munoz-Calvo MT, Barrios V, Garcia de Alvaro MT, et al. Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. Scand J Clin Lab Invest. 2007;67: 387-393.
31. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17: 200-209.
32. Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66: 100-103.
33. Stilgren L, Rettmer E, Eriksen E, Hegedus L, Beck-Nielsen H, Abrahamsen B. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-κB ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone. 2004;35: 256-265.
34. Anastasilakis AD, Polyzos SA, Toulis KA. Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge. Curr Opin Endocrinol Diabetes Obes. 2011;18: 383-388.
35. Nakashima T, HayashiM, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17: 1231-1234.
36. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280: 19883-19887.
37. Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39: 754-766.